Jay Herath/loyno.edu
Mar 24, 2026, 02:50
Jay Herath: Fitusiran Advancing Hemophilia Care Beyond Factor Replacement
Jay Herath, Professor of the Practice at Loyola University, shared a post on LinkedIn:
“Qfitlia (fitusiran), approved in 2025, is a first-in-class siRNA therapy that treats hemophilia A and B by targeting antithrombin-III mRNA in the liver.
Instead of replacing missing clotting factors (Factor VIII or IX), it reduces antithrombin levels, restoring the body’s ability to generate thrombin and form stable blood clots.”
Stay updated with Hemostasis Today.
-
Sep 14, 2026, 09:44Mohammad Salar Amoli: Thrombin The Master Regulator of Coagulation
-
Sep 14, 2026, 09:23Claire Harrison: HemaSphere Introduces New Patient Editor Role
-
Sep 14, 2026, 09:13Eirini Zorba: Plasmapheresis in Focus Understanding Its Role in Patient Care
-
Sep 14, 2026, 08:55Abdulrahman Al-Mashdali։ Immune Checkpoint Inhibitor Associated HLH
-
Sep 14, 2026, 07:54Islam Sadek: SOHO2026 Highlights Advances in Hematologic Malignancies
-
Sep 14, 2026, 07:45Flora Peyvandi: Building a More Equitable Future for Hemophilia Care
-
Sep 14, 2026, 07:37Joseph Pierre Aboumsallem: ET Treatment Enters a New Chapter
-
Sep 14, 2026, 07:29Eric Topol – Will AI Replace Clinicians?
-
Sep 14, 2026, 07:19Ruhi Mehra: The Evolving Science of Stem Cell Enumeration